|
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
RECRUITINGN/ASponsored by Columbia University
Actively Recruiting
PhaseN/A
SponsorColumbia University
Started2024-03-19
Est. completion2026-12-23
Eligibility
Age5 Years – 21 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT05963971
Summary
The purpose of this study is determine the effectiveness of a six-month virtually-delivered dietary education intervention (PEDALL) on the prevention of overweight and obesity (OW/OB) during maintenance chemotherapy in children and adolescents with acute lymphoblastic leukemia (ALL).
Eligibility
Age: 5 Years – 21 YearsHealthy volunteers accepted
Inclusion Criteria: * Age: 5-21 years old at enrollment * Diagnosis and Treatment: Plan to receive or are receiving maintenance or continuation chemotherapy for B- or T-cell ALL, or mixed phenotype acute leukemia. * Timing: Patient is eligible for entry only if it is feasible to start the study intervention during the first month of the maintenance phase of ALL therapy. * Language: Fluency in English or Spanish * Weight Status: Healthy weight at baseline as determined by BMI z-score \< 1.04 and \>-1.04 for those under 5-18, and BMI between 19 and 25 for those \>18. * Ethnicity: Hispanic or Non-Hispanic of any race. Exclusion Criteria: * Patients on nutrition support (enteral or parenteral nutrition) * Patients with a history of eating disorder
Conditions3
Acute Lymphoblastic LeukemiaCancerObesity
Locations1 site
Columbia University Medical Center
New York, New York, 10032
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorColumbia University
Started2024-03-19
Est. completion2026-12-23
Eligibility
Age5 Years – 21 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT05963971